Evidence map›Paper›PMID 21707950›Full record

ArticleClinical and translational science2011

A CTSA agenda to advance methods for comparative effectiveness research.

Mark Helfand, Sean Tunis, Evelyn P Whitlock, Stephen G Pauker, Anirban Basu, Jon Chilingerian, Frank E Harrell, David O Meltzer, Victor M Montori, Donald S Shepard and 2 more

Abstract read
In one paragraph

Article in Clinical and translational science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Multiple- vs Non- or Single-Imputation based Fuzzy Clustering for Incomplete Longitudinal Behavioral Intervention Data....IEEE...International Conference on Connected Health: Applications, Systems and Engineering Technologies. IEEE International Conference on Connected Health: Applications, Systems and Engineering Technologies · 2016
    Article
  5. Article
  6. Article
  7. Article
  8. A partnership of two U.S. research networks to improve public health.American journal of preventive medicine · 2013
    Article
  9. Review
  10. Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics.Medical decision making : an international journal of the Society for Medical Decision Making · 2013
    Article
  11. Article
  12. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.Genetics in medicine : official journal of the American College of Medical Genetics · 2012
    Review
  13. Article
  14. Article
  15. Role of practice-based research networks in comparative effectiveness research.Journal of comparative effectiveness research · 2012
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mark HelfandOregon Clinical & Translational Research Center, Oregon Health & Sciences University, and Department of Hospital and Specialty Medicine, The Portland VA Medical Center, Portland, OR, USA. helfand@ohsu.edu
Sean Tunis
Evelyn P Whitlock
Stephen G Pauker
Anirban Basu
Jon Chilingerian
Frank E Harrell
David O Meltzer
Victor M Montori
Donald S Shepard
David M Kent
Methods Work Group of the National CTSA Strategic Goal Committee on Comparative Effectiveness Research

Funding

TUFTS CLINICAL AND TRANSLATION SCIENCE INSTITUTE (UL1): BPCAUL1RR025752 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
$17.6M
Tufts Clinical and Translational Science Institute (K12)KL2RR025751 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
$596k
NCRR NIH HHS KL2 RR025751NCRR NIH HHS UL1 RR025752
6 · The paper itself

Abstract

Clinical research needs to be more useful to patients, clinicians, and other decision makers. To meet this need, more research should focus on patient-centered outcomes, compare viable alternatives, and be responsive to individual patients' preferences, needs, pathobiology, settings, and values. These features, which make comparative effectiveness research (CER) fundamentally patient-centered, challenge researchers to adopt or develop methods that improve the timeliness, relevance, and practical application of clinical studies. In this paper, we describe 10 priority areas that address 3 critical needs for research on patient-centered outcomes (PCOR): (1) developing and testing trustworthy methods to identify and prioritize important questions for research; (2) improving the design, conduct, and analysis of clinical research studies; and (3) linking the process and outcomes of actual practice to priorities for research on patient-centered outcomes. We argue that the National Institutes of Health, through its clinical and translational research program, should accelerate the development and refinement of methods for CER by linking a program of methods research to the broader portfolio of large, prospective clinical and health system studies it supports. Insights generated by this work should be of enormous value to PCORI and to the broad range of organizations that will be funding and implementing CER.

Indexed as

Clinical Trials as TopicComparative Effectiveness ResearchHumansNational Institutes of Health (U.S.)Outcome Assessment, Health CarePatient-Centered CareProgram DevelopmentProgram EvaluationResearch DesignTranslational Research, BiomedicalTreatment OutcomeUnited States

Identifiers

PMID21707950
PMCPMC4567896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.